Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.

Pharmacological research - 1 Nov 2025

Song Yuxuan, Jiang Shan, Peng Yun, Du Yiqing, Qin Caipeng, Xu Tao

Abstract excerpt

Dysregulation of fibroblast growth factor receptor (FGFR) signaling contributes to tumorigenesis and FGFRs have been clinically approved as treatment targets for FGFR inhibitor (FGFRi) in urothelial carcinoma (UC). The present study aimed to explore the correlations between different FGFR3 alteration sites and response to FGFRi. We involved a total of 1045 FGF/FGFR-altered UC patients treated with FGFRi, among...

Topics

Join the communities discussing this publication.

Carcinoma, Transitional Cell
Microtubule-Associated Proteins
Protein Kinase Inhibitors
Pyrazoles
Quinoxalines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Receptor, Fibroblast Growth Factor, Type 3

Urinary Bladder Neoplasms

Urologic Neoplasms

Source

Identifiers

PMID: 41005586
DOI: 10.1016/j.phrs.2025.107968

Genes

FGFR3
TACC3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.PMID 41005586Read ↗

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.Semantic proximity Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.Semantic proximity Read ↗

Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder.Semantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

Fibroblast growth factor receptor-3 in urothelial tumorigenesis.Semantic proximity Read ↗

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

The genetic difference between Western and Chinese urothelial cell carcinomas: infrequent FGFR3 mutation in Han Chinese patients.Semantic proximity Read ↗

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.